Haleon (LON:HLN) Price Target Lowered to GBX 335 at Deutsche Bank Aktiengesellschaft

Haleon (LON:HLN) had its target price trimmed by Deutsche Bank Aktiengesellschaft from GBX 340 to GBX 335 in a research report sent to investors on Thursday morning,London Stock Exchange reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently commented on HLN. Jefferies Financial Group reissued a “buy” rating and issued a GBX 450 price target on shares of Haleon in a research report on Wednesday. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 target price on shares of Haleon in a report on Friday, October 31st. JPMorgan Chase & Co. raised their price target on Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a report on Wednesday, November 26th. Finally, Berenberg Bank lifted their price target on Haleon from GBX 507 to GBX 517 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of GBX 407.83.

Haleon Trading Up 0.2%

Shares of LON HLN opened at GBX 378.10 on Thursday. Haleon has a 1 year low of GBX 325.10 and a 1 year high of GBX 419.50. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. The firm has a 50-day moving average of GBX 368.56 and a 200 day moving average of GBX 359.32. The stock has a market cap of £33.67 billion, a P/E ratio of 22.64, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.